Research programme: vanadium compounds - Angiotech
Latest Information Update: 16 Nov 2006
At a glance
- Originator Angiotech Pharmaceuticals
- Mechanism of Action Angiogenesis inhibitors; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Rheumatoid arthritis in Canada (Unknown route)
- 14 Aug 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 22 Jun 1998 Preclinical development for Cancer in Canada (Unknown route)